Ranibizumab, a mAb against VEGF-A for the potential treatment of age-related macular degeneration and other ocular complications

Current Opinion in Molecular Therapeutics

Volumn 9, Issue 6, 2007, Pages 592-602

  Lantry, L E ^a  

^a Bracco Research USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOPORPHYRIN DERIVATIVE; BEVACIZUMAB; MONOCLONAL ANTIBODY; PEGAPTANIB; RANIBIZUMAB; VASCULOTROPIN A;

AREA UNDER THE CURVE; CENTRAL RETINA VEIN OCCLUSION; CENTRAL SEROUS RETINOPATHY; CEREBROVASCULAR ACCIDENT; CHOROID DISEASE; CLINICAL TRIAL; CONJUNCTIVA TUMOR; CONJUNCTIVAL HEMORRHAGE; DIABETIC MACULAR EDEMA; DISEASE MODEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENDOPHTHALMITIS; EYE DISEASE; EYE INFLAMMATION; EYE PAIN; HEART INFARCTION; HUMAN; INJECTION SITE REACTION; INTRAOCULAR HYPERTENSION; IRIDOCYCLITIS; MOLECULAR WEIGHT; NONHUMAN; PHOTODYNAMIC THERAPY; POLYPOIDAL CHOROIDAL VASCULOPATHY; RETINA MACULA AGE RELATED DEGENERATION; RETINA VEIN OCCLUSION; REVIEW; SUBRETINAL NEOVASCULARIZATION; TELANGIECTASIA; UVEITIS; VITREOUS FLOATERS; VON HIPPEL LINDAU DISEASE;

ANIMALS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; CLINICAL TRIALS AS TOPIC; CONJUNCTIVAL NEOPLASMS; DIABETES COMPLICATIONS; HUMANS; MACULAR EDEMA; NEOVASCULARIZATION, PATHOLOGIC; TELANGIECTASIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VON HIPPEL-LINDAU DISEASE;

EID: 36549016627     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. 413104 Selection and analysis of an optimized anti-VEGF antibody: Crystal structure of an affinity-matured Fab in complex with antigen. Chen Y, Wiesmann C, Fuh G, Li B, Christinger HW, McKay P, de Vos AM, Lowman HB J MOL BIOL 1999 293 4 865-881
2. 413109 VEGF and the Fab fragment of a humanized neutralizing antibody: Crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface. Muller YA, Chen Y, Christinger HW, Li B, Cunningham BC, Lowman HB, de Vos AM STRUCTURE 1998 6 9 1153-1167
3. 420918 Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumours and other disorders. Presta LG, Chen H, O'Connor SJ CANCER RES 1997 57 20 4593-4599
4. 483716 Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Krzystolik MG, Afshari MA, Adamis AP, Gaudreault J, Gragoudas ES, Michaud NA, Li W, Connolly E, O'Neill CA, Miller JW ARCH OPHTHALMOL 2002 120 3 338-346
5. 483732 Vitreal pharmacokinetics of rhuFab V2 in rabbits using a non-invasive method. Gaudreault J, Escandon E, Maruoka M, Reich M, Li D, Hsei LL ANN MEET ASSOC RES VISION OPHTHALMOL 2002 43 Abs 2801
6. 489536 Status of therapies in development for the treatment of age-related macular degeneration. Hunt DWC, Margaron P IDRUGS 2003 6 5 464-469
7. 494711 Genentech licenses Lucentis to Novartis. Genentech Inc, Novartis AG PRESS RELEASE 2003 June 25
8. 508230 Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Kvanta A, Algvere PV, Berglin L, Seregard S INVEST OPHTHALMOL VIS SCI 1996 37 9 1929-1934
9. 508231 Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR INVEST OPHTHALMOL VIS SCI 1996 37 5 855-868
10. 508232 Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation. Wells JA, Murthy R, Chibber R, Nunn A, Molinatti PA, Kohner EM, Gregor ZJ BR J OPHTHALMOL 1996 80 4 363-366
11. 516877 Technology evaluation: Bevacizumab, Genentech/Roche. Salgaller ML CURR OPIN MOL THER 2003 5 6 657-667
12. 516879 Technology evaluation: Pegaptanib, Eyetech/Pfizer. Vinores SA CURR OPIN MOL THER 2003 5 6 673-679
13. 533328 Novel approaches to ocular drug delivery. Davis JL, Gilger BC, Robinson MR CURR OPIN MOL THER 2004 6 2 195-205
14. 538169 The biology of VEGF and its receptors. Ferrara N, Gerber H-P, LeCouter J NAT MED 2003 9 6 669-676
15. 620280 Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey. Husain D, Kim I, Gauthier D, Lane AM, Tsilimbaris MK, Ezra E, Connolly EJ, Michaud N, Gragoudas ES, O'Neill CA, Beyer JC et al ARCH OPHTHALMOL 2005 123 4 509-516
16. 632978 Genentech/Novartis's Lucentis displays superiority over Visudyne in wet AMD. Genentech Inc PRESS RELEASE 2005 November 07
17. 633055 Preliminary data from second pivotal phase III study showed Lucentis maintained or improved vision in 95 percent of patients with age-related macular degeneration (AMD). Novartis AG PRESS RELEASE 2005 November 07
18. 662997 Genentech development pipeline. Genetech Inc COMPANY WORLD WIDE WEB SITE 2006 March 31
19. 676639 Genentech's Lucentis approved in US for AMD. Genentech Inc PRESS RELEASE 2006 June 30
20. 731801 A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Chun DW, Heier JS, Topping TM, Duker JS, Bankert JM OPHTHALMOLOGY 2006 113 10 1706-1712
21. 731803 Ranibizumab for treatment of neovascular age-related macular degeneration - a phase I/II multicenter, controlled, multidose study. Heier JS, Antoszyk AN, Pavan PR, Leff SR, Rosenfeld PJ, Ciulla TA, Dreyer RF, Gentile RC, Sy JP, Hantsbarger G, Shams N OPHTHALMOLOGY 2006 113 4 633-644
22. 731805 Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Rosenfeld PJ, Heier JS, Hantsbarger G, Shams N OPHTHALMOLOGY 2006 113 4 623-632
23. 731806 Ranibizumab: Phase III clinical trial results. Rosenfeld PJ, Rich RM, Lalwani GA OPHTHALMOL CLIN N AM 2006 19 3 361-372
24. 731807 Effect of intravitreal injection of ranibizumab in combination with verteporfin PDT on normal primate retina and choroids. Kim IK, Husain D, Michaud N, Connolly E, Lane AM, Durrani K, Hafezi-Moghadam A, Gragoudas ES, O'Neill CA, Beyer JC, Miller JW INVEST OPHTHALMOL VIS SCI 2006 47 1 357-363
25. 731810 Long-term experience with Lucentis (ranibizumab) in patients with neovascular age-related macular degeneration (AMD). Heier JS, Rosenfeld PJ, Antoszyk AN, Hantsbarger G, Kim R, Shams N INVEST OPHTHALMOL VIS SCI 2005 46 Suppl S1393
26. 731811 Clinical pharmacokinetics of ranibizumab (Lucentis) in subjects with AMD. Haughney PC, Lowe J, Kearns A, Rusit J, Lakhani S, Damico LA, Xu L, Goudreault J INVEST OPHTHALMOL VIS SCI 2005 46 Suppl S1383
27. 731813 Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Rosenfeld PJ, Schwartz SD, Blumenkranz MS, Miller JW, Haller JA, Reimann JD, Greene WL, Shams N OPHTHALMOLOGY 2005 112 6 1048-1053
28. 731814 Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V INVEST OPHTHALMOL VIS SCI 2005 46 2 726-733
29. 731817 A pharmacokinetic model describing ocular and systemic disposition of ranibizumab in rabbits. Gaudreault J, Damico LA, Haughney PC, Reich M, Rusit J, Bender BB INVEST OPHTHALMOL VIS SCI 2004 45 Suppl 1 U730
30. 731818 Pharmacokinetic study of ranibizumab (Lucentis) following subconjunctival, intracameral and intravitreal administration in rabbits. Damico GA, Gaudreault J, Bender BC, Rusit J, Reich MP, Oldendorp A INVEST OPHTHALMOL VIS SCI 2004 45 Suppl 2 U341
31. 731826 Rhufab V2 inhibits VEGF-isoforms-stimulated HUVEC proliferation. Lowe J, Araujo J, Palma M, Wang Y, Gaudreault J, Yang J, Yu N, Fei D ANN MEET ASSOC RES VISION OPHTHALMOL 2003 44 Abs 1828
32. 731829 Ocular pharmacokinetics and antipermeability effect of rhufab V2 in animals. Gaudreault J, Reich M, Arata A, Rusit J, Pelletier N, Shiu V ANN MEET ASSOC RES VISION OPHTHALMOL 2003 44 Abs 3942
33. 731839 Ranibizumab versus verteporfin for neovascular age-related macular degeneration. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S N ENGL J MED 2006 355 14 1432-1444
34. 731843 Ranibizumab for neovascular age-related macular degeneration. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY N ENGL J MED 2006 355 14 1419-1431
35. 735327 Health Canada grants priority review for Lucentis for neovascular age-related macular degeneration. Novartis AG PRESS RELEASE 2006 October 26
36. 755725 NCT00406796: Lucentis for central retinal vein occlusion (CRVO). CLINICALTRIALS.GOV 2006 November 30
37. 756751 Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Nguyen QD, Tatlipinar S, Shah SM, Haller JA, Quinlan E, Sung J, Zimmer-Galler I, Do DV, Campochiaro PA AM J OPHTHALMOL 2006 142 6 961-969
38. 757426 Genentech Inc: Strong 4Q and 07 outlook; Raising target to $104. Ende E, Munno D, Newman J MERRILL LYNCH CO 2007 January 11
39. 760152 EU approves Novartis's Lucentis for the treatment of wet AMD. Novartis AG PRESS RELEASE 2007 January 24
40. 770167 Ranibizumab for the treatment of neovascular AMD. Kaiser PK, Do DV INT J CLIN PRACT 2007 61 3 501-509
41. 770169 Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR OPHTHALMOLOGY 2007 114 2 246-252
42. 770175 Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: Year 1 results of the FOCUS Study. Heier JS, Boyer DS, Ciulla TA, Ferrone PJ, Jumper JM, Gentile RC, Kotlovker D, Chung CY, Kim RY ARCH OPHTHALMOL 2006 124 11 1532-1542
43. 770203 Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Ferrara N, Damico L, Shams N, Lowman H, Kim R RETINA 2006 26 8 859-870
44. 777006 NCT00395551: Safety study of ranibizumab eye injections to treat choroidal neovascularization that was caused other than by agerelated macular degeneration. Genentech Inc CLINICALTRIALS.GOV 2006 November 02
45. 780638 Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Adamis AP, Shima DT, Tolentino MJ, Gragoudas ES, Ferrara N, Folkman J, D'Amore PA, Miller JW ARCH OPHTHALMOL 1996 114 1 66-71
46. 780645 Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, Ferrara N, King GL, Smith LE PROC NATL ACAD SCI USA 1995 92 23 10457-10461
47. 780648 Antibody humanization using monovalent phage display. Baca M, Presta LG, O'Connor SJ, Wells JA J BIOL CHEM 1997 272 16 10678-10684
48. 780650 Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation. Blaauwgeers HG, Holtkamp GM, Rutten H, Witmer AN, Koolwijk P, Partanen TA, Alitalo K, Kroon ME, Kijlstra A, van Hinsbergh VW, Schlingemann RO AM J PATHOL 1999 155 2 421-428
49. 780651 Self-reported vision-specific quality of life at 1 year in patients with neovascular age-related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis). Chang TS, Fine JT, Bressler N INVEST OPHTHALMOL VIS SCI 2006 47 Abs 5252
50. 780660 Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA study): Results of a phase 1 dose-escalation study. Costa RA, Jorge R, Calucci D, Cardillo JA, Melo LAS-Jr, Scott IU INVEST OPHTHALMOL VIS SCI 2006 47 10 4569-4578
51. 780664 Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study). Costa RA, Jorge R, Calucci D, Melo LA Jr, Cardillo JA, Scott IU GRAEFES ARCH CLIN EXP OPHTHALMOL 2007 245 9 1273-1280
52. 780670 The International Intravitreal Bevacizumab Safety Survey: Using the internet to assess drug safety worldwide. Fung AE, Rosenfeld PJ, Reichel E BR J OPHTHALMOL 2006 90 11 1344-1349
53. 780675 Human retinal molecular weight exclusion limit and estimate of species variation. Jackson TL, Antcliff RJ, Hillenkamp J, Marshall J INVEST OPHTHALMOL VIS SCI 2003 44 5 2141-2146
54. 780679 An emerging problem: Recurrence of CNV in AMD is common after cessation of 24 month treatment with ranibizumab (Lucentis). Korotkin A, Kozak I, Morrison VL, Magana L, Freeman WR INVEST OPHTHALMOL VIS SCI 2006 47 Abs 2961
55. 780682 VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Lambrechts D, Storkebaum E, Morimoto M, Del-Favero J, Desmet F, Marklund SL, Wyns S, Thijs V, Andersson J, van Marion I, Al-Chalabi A et al NAT GENET 2003 34 4 383-394
56. 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Mordenti J, Cuthbertson RA, Ferrara N, Thomsen K, Berleau L, Licko V, Allen PC, Valverde CR, Meng YG, Fei DT, Fourre KM et al TOXICOL PATHOL 1999 27 5 536-544
57. 780686 Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: Twenty-four-week results of an uncontrolled open-label clinical study. Moshfeghi AA, Rosenfeld PJ, Puliafito CA, Michels S, Marcus EN, Lenchus JD, Venkatraman AS OPHTHALMOLOGY 2006 113 11 2002-2011
58. 780688 Visual acuity outcomes following a variable-dosing regimen for ranibizumab (Lucentis) in neovascular AMD: The PrONTO study. Rosenfeld PJ, Fung AE, Lalwani GA, Michels S, Venkatraman AS, Puliafito CA INVEST OPHTHALMOL VIS SCI 2006 47 Abs 2958
59. 780691 Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells. Spitzer MS, Yoeruek E, Sierra A, Wallenfels-Thilo B, Schraermeyer U, Spitzer B, Bartz-Schmidt KU, Szurman P GRAEFES ARCH CLIN EXP OPHTHALMOL 2007 doi:10.1007/s00417-007-0568-7
60. 790728 An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HWJ, Esquiabro M AM J OPHTHALMOL 2007 143 4 566-583
61. 802625 Vascular diseases. Garner A PATHOBIOLOGY OCULAR DIS - 2ND EDITION (Garner A, Klintworth GK EDS) 1994 1625-1710
62. 802647 Electron microscopic studies of intra-retinal spaces: Diffusion of particulate materials. Smelser G, Ishikawa T, Pei Y EYE STRUCTURE (Rohen J ED) 1965 109
63. 802652 Optical coherence tomography findings in a variable-dosing regimen with ranibizumab (Lucentis): The PrONTO study. Lalwani G, Fung AE, Michels S, Venkatraman AS, Puliafito CA, Rosenfeld PJ ANN MEET ASSOC RES VISION OPHTHALMOL 2006 May 01 B726
64. 802657 Lucentis (ranibizumab injection) highlights of prescribing information. Genentech Inc COMPANY PUBLICATION 2006 June
65. 812472 Genentech Announces Second Quarter 2007 Results. Genentech Inc PRESS RELEASE 2007 July 11
66. 813559 Novartis delivers strong performance in first half of 2007 (H1 report). Novartis AG PRESS RELEASE 2007 July 17
67. 831978 Product update: New product - Lucentis. Novartis Opthalmics AG MIMS (LONDON) 2007 April 10
68. 839180 Causes and prevalence of visual impairment among adults in the United States. Congdon N, O'Colmain B, Klaver CC, Klein R, Munoz B, Friedman DS, Kempen J, Taylor HR, Mitchell P ARCH OPHTHALMOL 2004 122 4 477-485
69. 839183 Age-related macular degeneration and blindness due to neovascular maculopathy. Ferris FL 3rd, Fine SL, Hyman L ARCH OPHTHALMOL 1984 102 11 1640-1642
70. 839197 The price of sight - ranibizumab, bevacizumab, and the treatment of macular degeneration. Steinbrook R N ENGL J MED 2006 355 14 1409-1412
71. 840248 Ranibizumab (Lucentis) 0.5 mg increases stroke risk. Genentech Inc COMPANY NEWSLETTER 2007 January 24